Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US0008991046
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG002NCK5M5
ADMA
ADMA Biologics Inc
GICS: Health Care · SECTOR: Healthcare · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
ADMA Biologics Inc
ISIN
US0008991046
TICKER
ADMA
MIC
XNAS
REUTERS
ADMA.OQ
BLOOMBERG
ADMA US
Mi., 30.10.2024       ADMA Biologics
US0008991046

New York, New York--(Newsfile Corp. - October 30, 2024) - Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://w...
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
Di., 29.10.2024       ADMA Biologics
US0008991046

Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ADMA Biologics Inc (“ADMA Biologics” or “the Company”) (NASDAQ: ADMA). Investors who purchased ADMA Biologics securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site:...
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
Di., 29.10.2024       ADMA Biologics
US0008991046

Conference Call Scheduled for November 7, 2024, at 4:30 p.m. ET Conference Call Scheduled for November 7, 2024, at 4:30 p.m. ET...
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
Mo., 28.10.2024       ADMA Biologics
US0008991046

Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ADMA Biologics Inc (“ADMA Biologics” or “the Company”) (NASDAQ: ADMA). Investors who purchased ADMA Biologics securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site:...
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
Mo., 28.10.2024       ADMA Biologics
US0008991046

New York, New York--(Newsfile Corp. - October 28, 2024) -   Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting ht...
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
Fr., 25.10.2024       ADMA Biologics
US0008991046

New York, New York--(Newsfile Corp. - October 25, 2024) - Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws.If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://ww...
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
Fr., 25.10.2024       ADMA Biologics
US0008991046

NEW YORK, Oct. 25, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
Do., 24.10.2024       ADMA Biologics
US0008991046

New York, New York--(Newsfile Corp. - October 24, 2024) - Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://w...
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
Di., 22.10.2024       ADMA Biologics
US0008991046

New York, New York--(Newsfile Corp. - October 22, 2024) - Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws.If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://ww...
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
So., 20.10.2024       ADMA Biologics
US0008991046

New York, New York--(Newsfile Corp. - October 20, 2024) - Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://w...
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Fr., 18.10.2024       ADMA Biologics
US0008991046

New York, New York--(Newsfile Corp. - October 18, 2024) - Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws.If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://ww...
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
Do., 17.10.2024       ADMA Biologics
US0008991046

NEW YORK, Oct. 17, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
Mi., 16.10.2024       ADMA Biologics
US0008991046

New York, New York--(Newsfile Corp. - October 16, 2024) - Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://w...
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
Di., 15.10.2024       ADMA Biologics
US0008991046

Boston, Massachusetts--(Newsfile Corp. - October 15, 2024) - Block & Leviton is investigating ADMA Biologics, Inc. (NASDAQ: ADMA) for potential securities law violations. Investors who have lost money in their ADMA Biologics investment should contact the firm to learn more about how they might recover those losses. For more details, visit https...
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
Mo., 14.10.2024       ADMA Biologics
US0008991046

New York, New York--(Newsfile Corp. - October 14, 2024) - Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://w...
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
Sa., 12.10.2024       ADMA Biologics
US0008991046

New York, New York--(Newsfile Corp. - October 12, 2024) - Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://w...
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
Do., 10.10.2024       ADMA Biologics
US0008991046

New York, New York--(Newsfile Corp. - October 10, 2024) -  Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting htt...
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
Di., 17.09.2024       ADMA Biologics
US0008991046

RAMSEY, N.J. and BOCA RATON, Fla., Sept. 17, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced it will join the S&P SmallCap 600 index, effective prior to the open of trading on Mon...
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
Di., 10.09.2024       ADMA Biologics
US0008991046

RAMSEY, N.J. and BOCA RATON, Fla., Sept. 10, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced Adam Grossman, President and Chief Executive Officer, will participate in...
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
Do., 01.08.2024       ADMA Biologics
US0008991046

Conference Call Scheduled for August 8, 2024, at 4:30 p.m. ET Conference Call Scheduled for August 8, 2024, at 4:30 p.m. ET...
Zur Nachricht
ADMA Biologics
Charts & Research Termsheets Terminal
Permalink
Silent Ad